MYALEPT is the first and only FDA-approved leptin replacement therapy1

MYALEPT, as an adjunct to diet, treats the complications of leptin deficiency in patients with generalized lipodystrophy.

MYALEPT replaces native leptin, a hormone predominantly secreted by adipose tissue that informs the central nervous system (CNS) of the status of energy stores in the body.

MYALEPT exerts its function by binding to and activating the human leptin receptor in the hypothalamus. 

Improvements in insulin sensitivity and reductions in food intake are consistent with lower HbA1c, fasting glucose, and fasting triglyceride values that were seen in the MYALEPT clinical trial. Learn more about the MYALEPT clinical trial